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Introduction {#sec1}
============

Human endothelial colony-forming cells (ECFCs) are endothelial progenitors that can be isolated from umbilical cord blood and peripheral blood ([@bib24], [@bib32], [@bib33]) or derived from induced pluripotent stem cells (iPSCs) ([@bib41]). These highly proliferative cells possess the unique property of forming functional blood vessels *in vivo* upon transplantation ([@bib3], [@bib34], [@bib43], [@bib50]). This property distinguishes ECFCs from more mature endothelial cells and makes them particularly attractive as a cell therapy for enhanced vascular repair in ischemic diseases such as peripheral arterial disease, ischemic retinopathy, myocardial infarction, or stroke ([@bib12], [@bib19], [@bib21], [@bib40], [@bib46]). Upon transplantation at sites of ischemic injury, ECFCs incorporate into damaged blood vessels and release pro-angiogenic growth factors to facilitate the repair process, ultimately improving blood perfusion and organ function ([@bib1], [@bib6], [@bib38], [@bib44], [@bib45]). Furthermore, ECFCs can be used to provide trophic support to other therapeutically relevant cells ([@bib31]). While ECFCs represent promising candidates for cell therapy, it is critical to improve their efficacy *in vivo* through promoting cell survival and increasing the kinetics of cell migration, homing, differentiation, and secretion of pro-angiogenic factors ([@bib11], [@bib12]).

Studies in endothelial cells have identified several signal transduction pathways (e.g., CXCR4, VEGF, NOTCH, SHH, and WNT) that coordinate survival, differentiation, arterial/venous specification, and blood-vessel morphogenesis ([@bib9], [@bib23], [@bib29]). Therefore, a major question is how to activate pro-angiogenic signaling pathways in ECFCs such that we can boost the regenerative function of these cells and increase their survival *in vivo* post transplantation. Promising results have been obtained through pre-activation of the NOTCH pathway where it was shown that the vascular repair potential of transplanted murine endothelial progenitors is significantly increased if the cells are cultured *ex vivo* with stromal cells overexpressing the Notch ligand Jag-1 prior to transplantation ([@bib28]). Furthermore, it was recently found that co-implantation of stromal cells expressing the Notch ligand Dll1 decreases apoptosis and enhances the post-natal vasculogenic capacity of human ECFCs in murine subcutaneous implants ([@bib26]). While activation of the Notch pathway through external stimulation of Notch receptors may provide a valuable strategy to enhance vascular repair properties of endothelial progenitors, several other signaling pathways (e.g., VEGFR, CXCR4, SHH, WNT) are also essential for angiogenesis and post-natal vasculogenesis. However, an approach that simultaneously activates multiple pro-angiogenic pathways in ECFCs is currently lacking.

We previously demonstrated that *ex vivo* treatment with the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) increases ECFC-mediated vascular repair in hindlimb ischemia ([@bib38]), providing proof of principle that the priming of ECFCs with epigenetic drugs prior to transplantation is a valuable strategy to improve their regenerative function ([@bib21]). Stem and progenitor cells are characterized by a high prevalence of transcriptionally competent but repressed (i.e., "poised") genes that are marked by both active (histone H3 lysine 4 trimethylation \[H3K4me3\]) and repressive (histone H3 lysine 27 trimethylation \[H3K27me3\]) histone modifications that play important roles in differentiation and development ([@bib4], [@bib49]). While those bivalent genes are expressed at extremely low levels, it has been proposed that the presence of H3K4me3 may prime them for rapid activation upon removal of H3K27me3. Here, we set out to test the hypothesis that decreasing the levels of the repressive mark H3K27me3 with epigenetic drugs could improve the vascular repair properties of ECFC through activation of pro-angiogenic signaling pathways.

Results {#sec2}
=======

A Combination of Epigenetic Drugs Increases ECFC Migration, Capillary Network Formation, and Resistance to Serum Starvation-Induced Apoptosis {#sec2.1}
---------------------------------------------------------------------------------------------------------------------------------------------

Repressive histone marks H3K27me2/3 are established on chromatin by the polycomb group repressive complex 2 (PRC2), a protein complex comprised of three core subunits: methyltransferase EZH2 and two other proteins, EED and SUZ12, both of which are required for PRC2 catalytic activity ([@bib17]). To decrease H3K27me2/3 levels, we treated human umbilical cord blood-derived ECFCs with GSK-343, a potent and selective inhibitor of EZH2 ([@bib48]). As expected, GSK-343 exposure led to a global decrease of H3K27me2/3 levels in a time- and dose-dependent manner ([Figures 1](#fig1){ref-type="fig"}A, [S1](#mmc1){ref-type="supplementary-material"}A, and S1B). Importantly, other histone marks, such as H3K27me1, H3K4me3, H3K9me3, H4K20me3, or histone acetylation, are not affected ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}B). Furthermore, GSK-343 does not lead to a decrease of PRC2 subunits nor does it alter the level of other chromatin-modifying enzymes, including the acetyltransferase P300, the deacetylase HDAC1, the H3K27 demethylase UTX, the H3K9 methyltransferase G9a, or the DNA methyltransferases DNMT1 and DNMT3A ([Figure 1](#fig1){ref-type="fig"}B). This is in contrast to the widely used S-adenosylhomocysteine hydrolase inhibitor 3-deazaneplanocin (DZNep), which depletes PRC2 subunits and leads to a global decrease of multiple histone marks, including H3K27me2/3 but also H4K20me3, H3K9me3, H3K4me3, and others ([@bib22], [@bib36], [@bib37], [@bib47]). Thus, in contrast to DZNep, GSK-343 is a potent and selective inhibitor of EZH2 in ECFCs.Figure 1Pharmacologic Treatment with a Combination of EZH2 and HDAC Inhibitors Enhances ECFC Migration, Capillary Network Formation, and Resistance to Serum Starvation-Induced Apoptosis(A) GSK-343 and panobinostat lead to a global decrease in H3K27me2/3 levels and an increase in H3/H4-acetyl levels, respectively, as analyzed by western blot. Molecular masses are indicated in kDa. Total histone H3 and H4 serve as loading controls.(B) GSK-343 and panobinostat do not affect the overall level of indicated proteins, as analyzed by western blot. Molecular masses are indicated in kDa. Tubulin serves as a loading control.(C) GSK-343 and panobinostat increase the kinetics of ECFC migration as measured by gap closure assay. Left: representative pictures of ECFCs stained with crystal violet after 10 hr migration (10× magnification; scale bar, 250 μm). Dashed circles represent the gap area prior to cell migration. Right: fraction of the gap area invaded by migrating cells at the indicated times. Average from thee independent experiments (n = 3) each performed in duplicate are shown ±SEM.(D) GSK-343 and panobinostat increase ECFC-mediated capillary-like structure formation on Matrigel. Left: representative pictures of capillary-like structures stained with calcein (2.5× magnification; scale bar, 1 mm). Right: total capillary length of the network is expressed as the mean percentage of control values corresponding to cells treated with vehicle ±SEM. Data shown from three independent experiments (n = 3) each performed in duplicate.(E) GSK-343 and panobinostat do not induce apoptosis in ECFCs as measured by fluorescence-activated cell sorting (FACS) after 7-AAD and annexin V staining.(F) GSK-343 and panobinostat reduce serum starvation-induced apoptosis in ECFCs as measured by FACS after 7-AAD and annexin V staining. ECFCs were grown in serum-containing EGM-2 medium or serum-depleted EBM-2 medium.(E and F) Data expressed as mean percentage of control values corresponding to cells treated with vehicle ±SEM from three independent experiments (n = 3), each performed in duplicate.(G) GSK-343 and panobinostat decrease ECFC proliferation as analyzed by bromodeoxyuridine (BrdU) incorporation. The percentage of cells incorporating BrdU is indicated ±SEM from four independent experiments (n = 4), each performed in duplicate.^∗∗∗^p \< 0.001; ^∗∗^p \< 0.01; ^∗^p \< 0.05; ns, non-significant. See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

Next, we examined the effects of GSK-343 on the capacity of ECFCs to migrate (using a gap closure assay) and to form a capillary-like network on Matrigel. These experiments revealed that GSK-343 significantly improves the pro-angiogenic properties of ECFCs, increasing both the kinetics of cell migration ([Figure S1](#mmc1){ref-type="supplementary-material"}C) and the capacity of ECFCs to form a capillary-like network ([Figure S1](#mmc1){ref-type="supplementary-material"}D) in a dose-dependent manner. Consistent with this, we found that knocking down EZH2 also increases ECFC-mediated capillary network formation (data not shown). Thus, inhibition of EZH2 is an efficient strategy to improve the angiogenic properties of ECFCs *in vitro*.

We showed previously that pre-treatment with the histone deacetylase (HDAC) inhibitor TSA increases ECFC-mediated capillary network formation ([@bib38]). Since GSK-343 has no effect on histone acetylation ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}B), we hypothesized that combining EZH2 and HDAC inhibitors may further improve ECFC function by acting on complementary epigenetic pathways. To test this hypothesis, we sought to use the highly potent class I, II, and IV HDAC inhibitor panobinostat (LBH589), which is less toxic than TSA and is already clinically approved for cancer treatment ([@bib2], [@bib18]). First, we confirmed that panobinostat used as a single agent is at least as efficient as TSA for improving the pro-angiogenic capacity of ECFCs, increasing both cell migration ([Figure S2](#mmc1){ref-type="supplementary-material"}D) and capillary network formation ([Figure S2](#mmc1){ref-type="supplementary-material"}E). Furthermore, we confirmed that, at the established optimal conditions (i.e., 10 nM for 2 hr), panobinostat leads to a significant increase in the global levels of histone H3 and H4 acetylation without affecting H3K27me3 or other histone modifications ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2C and [1](#fig1){ref-type="fig"}A). Having established optimal conditions for GSK-343 and panobinostat treatments as single agents, we combined these epigenetic drugs to determine whether we could further improve the pro-angiogenic functions of ECFCs. These experiments show that a combined treatment consisting of 72 hr incubation with the EZH2 inhibitor GSK-343 at 5 μM and 2 hr incubation with the HDAC inhibitor panobinostat at 10 nM is significantly more efficient at increasing the migration kinetics of ECFCs ([Figure 1](#fig1){ref-type="fig"}C) and capillary network formation ([Figure 1](#fig1){ref-type="fig"}D) than either drug alone. Furthermore, the combined treatment is specific to H3K27 di- and tri-methylation and to H3- and H4-acetylation without affecting other histone marks ([Figure 1](#fig1){ref-type="fig"}A) and without altering the levels of the enzymes responsible for H3K27 methylation/demethylation and H3/H4 acetylation/deacetylation ([Figure 1](#fig1){ref-type="fig"}B). We also verified that the drug combination does not induce apoptosis as measured by annexin V staining ([Figure 1](#fig1){ref-type="fig"}E). Rather, we found that treatment with GSK-343 and panobinostat increases the resistance of ECFCs to serum starvation-induced apoptosis ([Figure 1](#fig1){ref-type="fig"}F). Finally, we noted a slight decrease in ECFC proliferation upon drug treatment ([Figure 1](#fig1){ref-type="fig"}G). Thus, a combined treatment using an EZH2 inhibitor followed by an HDAC inhibitor is an efficient strategy to enhance the pro-angiogenic properties of ECFCs and increase their resistance to apoptosis.

Combined Treatment of ECFCs with Epigenetic Drugs Activates Multiple Pro-angiogenic Pathways Simultaneously {#sec2.2}
-----------------------------------------------------------------------------------------------------------

To better understand the mechanism through which the combined treatment of GSK-343 and panobinostat increases the pro-angiogenic properties of ECFCs, we measured changes in gene expression by RNA sequencing (RNA-seq) immediately upon drug treatment (i.e., 72 hr incubation with the EZH2 inhibitor GSK-343 at 5 μM followed by 2 hr incubation with the HDAC inhibitor panobinostat at 10 nM). This experiment, performed using two independently generated ECFC clones from two distinct cord blood donors, identified 553 upregulated genes and 329 downregulated genes (p \< 0.05) ([Figure 2](#fig2){ref-type="fig"}A). RNA-seq results were confirmed by qRT-PCR for all genes tested ([Figures 3](#fig3){ref-type="fig"}A, [S4](#mmc1){ref-type="supplementary-material"}, [S5](#mmc1){ref-type="supplementary-material"}A, and data not shown). Gene ontology (GO) analysis indicates that upregulated genes are enriched in categories related to blood-vessel development, cell motion, cell adhesion, and response to wounding ([Figures 2](#fig2){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}A), which confirms that the epigenetic drug combination increases the pro-angiogenic properties of ECFCs. In contrast, downregulated genes are enriched in categories related to cell division and proliferation, consistent with the slight decrease in cell proliferation observed upon drug treatment ([Figure 1](#fig1){ref-type="fig"}G). See [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"} for a complete list of changing genes and GO categories. Most interestingly, a pathway analysis identified NOTCH and WNT (wingless-type mouse mammary tumor virus integration site) transduction pathways as being significantly enriched for activated genes ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Furthermore, we noticed that three additional pro-angiogenic pathways, CXCR4 (for C-X-C chemokine receptor type 4), VEGFR (for vascular endothelial growth factor receptor), and SHH (for sonic hedgehog), are also activated upon drug treatment ([Figure 2](#fig2){ref-type="fig"}C). All five transduction pathways activated by the epigenetic drug combination have previously demonstrated pro-angiogenic roles, with VEGFR being a master regulator of all aspects of angiogenesis and vasculogenesis (including cell survival, proliferation, migration, differentiation, and morphogenesis), CXCR4 promoting endothelial progenitor cell migration, and homing, while NOTCH, WNT, and SHH pathways play critical roles in regulating vessel formation, branching, and maturation ([@bib9], [@bib11], [@bib16], [@bib23], [@bib29], [@bib39]). Interestingly, for each signaling pathway, upregulated genes belong to ligands, receptors, and downstream target genes ([Figure 2](#fig2){ref-type="fig"}C), which indicates global activation upon drug treatment. For instance, ligands (*DKK3*, *WNT5A*, *WNT9A*, *WNT4*, and *WNT11*), receptors (*FZD2*, *FZD1*, *FZD5*, and *FZD7*), and target genes (*TCF7L1*, *JAG1*, *MML1*, and *EGR1*) of the WNT pathway are activated ([Figure 2](#fig2){ref-type="fig"}C and see [Figures S3](#mmc1){ref-type="supplementary-material"}D and [S4](#mmc1){ref-type="supplementary-material"} for selected examples). Furthermore, negative regulators of WNT and VEGFR pathways (e.g., *DKK1* as well as *SEMA3A*) are downregulated ([Figure 2](#fig2){ref-type="fig"}C). Noticeably, parsing the genes in categories according to their expression levels reveals that the drug combination activates low-to-moderately expressed genes (e.g., *CXCL12*, *FZD7*, *DLL1*, *SHH*, *CXCR4*, *DLL4*), whereas genes that are already expressed at high levels (e.g., the transcription elongation factor gene *ELP3* or the endothelial nitric oxide synthase \[eNOS\] gene *NOS3*; [@bib10]) are not significantly affected ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Finally, we confirmed activation of the identified pro-angiogenic pathways at the protein level by western blot where we detected increased levels of VEGFR1, VEGFR2, intracellular NOTCH, and CXCR4, as well as increased phosphorylation of VEGFR2, AKT, and ERK1/2 proteins ([Figure 2](#fig2){ref-type="fig"}D). Taken together, these results indicate that in ECFCs, pro-angiogenic pathways are maintained in a repressed/poised state. Most importantly, we found that five major pro-angiogenic transduction pathways can be activated in ECFCs through the combined action of the epigenetic drugs GSK-343 and panobinostat. Thus, multiple pro-angiogenic signaling pathways can be activated simultaneously in endothelial progenitors through *ex vivo* drug treatment.Figure 2Pharmacologic Treatment of ECFCs with a Combination of EZH2 and HDAC Inhibitors Activates Multiple Pro-angiogenic Pathways Simultaneously(A) Global changes in gene expression upon drug treatment versus vehicle treatment analyzed by RNA-seq. Scatterplot shows upregulated (red) and downregulated (green) genes (n = 3).(B) Representative Gene Ontology (GO) Biological Process categories significantly enriched for up- and downregulated genes in ECFCs treated with GSK-343 and panobinostat.(C) Heatmaps of up- and downregulated genes that belong to the indicated signaling pathways as identified by RNA-seq analysis and validated by qRT-PCR (^∗^). Data are expressed in log2(FPKM) (n = 3). The feedback arrow indicates a gene belonging to both receptor and target gene categories.(D) Validation of cell-signaling pathway activation upon drug treatment at the protein level. Left: western blot analysis of ECFC extracts shows an increase in global protein levels of VEGFR1 (*FLT1*), VEGFR2 (*KDR*), cleaved intracellular domain of NOTCH1 (NOTCH1-NICD), and CXCR4 upon drug treatment. Middle: western blot analysis of VEGFR2 immunoprecipitates (IP) shows an increase in phospho-VEGFR2 upon drug treatment. Right: western blot analysis of ECFC extracts shows an increase in phospho-AKT and phospho-ERK1/2 upon drug treatment. Tubulin is used as a loading control. Molecular masses are indicated in kDa.See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"} as well as [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}.Figure 3Pharmacologic Treatment of ECFCs with a Combination of EZH2 and HDAC Inhibitors Increases Gene Expression through H3K27me3 Demethylation and Histone H3 Acetylation(A) Transcript levels of indicated genes were measured by qRT-PCR following treatment of ECFCs with vehicle, GSK-343, panobinostat, or GSK-343-panobinostat combination, as indicated. qRT-PCR values are expressed as mean percentages of vehicle-treated cells ±SEM with *B2M* serving as internal control. (n ≥ 3). ^∗∗∗^p \< 0.001; ^∗^p \< 0.05; ns, non-significant.(B) RNA polymerase II (pol II) binding to indicated gene promoters was assessed by ChIP-qPCR.(C--E) Enrichment of H3K27me3 (C), H3K4me3 (D), and H3 acetyl (E) histone marks to indicated gene promoters was assessed by ChIP-qPCR.(B--E) ChIPs were performed using indicated antibodies (Ab) or IgG as a negative control (Mock). qPCR values are expressed as mean fractions of input ±SD.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Activation of Pro-angiogenic Pathways by Epigenetic Drugs Occurs through Resolving Bivalently Marked Genes {#sec2.3}
----------------------------------------------------------------------------------------------------------

To better understand the mechanism of action of panobinostat and GSK-343, we further dissected the effect of these drugs (alone and in combination) on genes representative of various pathways. Interestingly, even though all genes tested are significantly increased upon treatment with the drug combination (validating our RNA-seq results), some genes respond to both drugs in a seemingly additive fashion (e.g., *FZD7*, *KDR*, *DLL4*, *HEY2*) while others appear to be more responsive to the HDAC inhibitor (e.g., *DLL1*, *SHH*) or to the EZH2 inhibitor (e.g., *CXCR4*, *CXCL12*, *ANGPT2*) with *ELP3* serving as a control not altered by drug treatment ([Figures 3](#fig3){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}). These differential effects on gene expression are reflected by differential RNA polymerase II (pol II) binding on gene promoters ([Figure 3](#fig3){ref-type="fig"}B). Then, we examined the effects of the drugs (alone and in combination) on histone post-translational modifications (PTMs). Consistent with their highly specific effects on global histone PTMs levels ([Figures 1](#fig1){ref-type="fig"}A, [S1](#mmc1){ref-type="supplementary-material"}B, and [S2](#mmc1){ref-type="supplementary-material"}C), we found that both drugs modify their respective targets without affecting other histone PTMs. Specifically, the EZH2 inhibitor GSK-343 decreases the repressive histone mark H3K27me3 on all three representative genes ([Figure 3](#fig3){ref-type="fig"}C) with no effect on H3K4me3 ([Figure 3](#fig3){ref-type="fig"}D) or H3-Ac ([Figure 3](#fig3){ref-type="fig"}E). Similarly, the HDAC inhibitor panobinostat increases histone H3 acetylation on all genes tested ([Figure 3](#fig3){ref-type="fig"}E) with no effect on H3K27me3 ([Figure 3](#fig3){ref-type="fig"}C) or H3K4me3 ([Figure 3](#fig3){ref-type="fig"}D). Taken together, these results indicate that the combination of GSK-343 and panobinostat increases gene expression in ECFCs through a mechanism that entails removal of the repressive histone mark H3K27me3 and increase in the active histone mark H3-Ac.

Interestingly, these experiments also revealed several properties of the genes that respond to the drug combination, including (1) the presence of both active (H3K4me3 and H3-Ac) and repressive (H3K27me3) histone marks on their promoter ([Figures 3](#fig3){ref-type="fig"}C, 3D, and 3E); (2) low, but detectable pol II binding on their promoter ([Figure 3](#fig3){ref-type="fig"}B); and (3) a low level of expression ([Figure S3](#mmc1){ref-type="supplementary-material"}C). These properties characterize a particular sort of genes named "bivalent" that are maintained in a state of equilibrium between full repression and full activation ([@bib4], [@bib49]). Even though bivalent genes are found in differentiated cells, they are more prevalent in stem/progenitor cells (e.g., [@bib14], [@bib25], [@bib35]), and they are poised to respond quickly (positively or negatively) to signaling cues from the environment ([@bib4], [@bib49]). Bivalent genes differ both from highly expressed genes (e.g., *ELP3* and *NOS3*) that are devoid of the repressive mark H3K27me3 ([Figures 3](#fig3){ref-type="fig"} and [S5](#mmc1){ref-type="supplementary-material"}) and from completely repressed genes (e.g., the non-endothelial genes *PAX7* and *MYOD*) that are devoid of the active marks H3K4me3 and H3-Ac and do not display pol II binding ([Figure S5](#mmc1){ref-type="supplementary-material"}).

To better understand the mechanism leading to H3K27me3 removal and H3-Ac increase upon drug treatment, we tested for binding of the epigenetic enzymes responsible for adding/removing these histone modifications. Interestingly, we found that bivalent gene promoters are co-bound by enzymes with antagonistic activities: (1) the H3K27 methyltransferase EZH2 and the H3K27 demethylase UTX, as well as (2) the histone acetyltransferase P300 and the histone deacetylase HDAC1 ([Figure 4](#fig4){ref-type="fig"}). Furthermore, these enzymes remain tethered to the genes upon drug treatment (data not shown). In contrast, EZH2 is not bound to the promoter of the highly expressed *ELP3* gene ([Figure 4](#fig4){ref-type="fig"}A), consistent with the absence of H3K27me3 at this site ([Figure 3](#fig3){ref-type="fig"}C). Taken together, these results suggest that in non-treated ECFCs, EZH2 and UTX compete for methylation/demethylation of H3K27 at bivalent gene promoters, resulting in an enrichment of the repressive histone mark H3K27me3 ([Figure 3](#fig3){ref-type="fig"}C) that is sufficient to maintain low levels of gene expression (i.e., poised status) ([Figures 3](#fig3){ref-type="fig"}A, [4](#fig4){ref-type="fig"}E, [S3](#mmc1){ref-type="supplementary-material"}C, S3D, and [S4](#mmc1){ref-type="supplementary-material"}). When EZH2 is inhibited (upon GSK-343 treatment), the equilibrium is displaced in favor of UTX, which rapidly removes the repressive mark H3K27me3 ([Figure 3](#fig3){ref-type="fig"}C), leading to increased gene transcription ([Figures 3](#fig3){ref-type="fig"}A, [4](#fig4){ref-type="fig"}E, [S3](#mmc1){ref-type="supplementary-material"}C, and S3D). A similar mechanism appears to be in place for histone acetylation/deacetylation where P300 and HDAC1 are co-bound to bivalent gene promoters ([Figure 4](#fig4){ref-type="fig"}) and compete for histone modification, resulting in increased acetylation upon panobinostat-mediated inhibition of HDAC activity ([Figure 3](#fig3){ref-type="fig"}E). Thus, ECFCs maintain specific genes in a repressed/poised state through the recruitment of antagonistic "activating" and "repressive" chromatin-modifying enzymes that establish a bivalent gene promoter status characterized by the presence of both active (H3K4me3 and H3-Ac) and repressive (H3K27me3) histone marks ([Figure 4](#fig4){ref-type="fig"}E). Importantly, this poised/bivalent status can be resolved through pharmacologic inhibition of the repressive enzymes EZH2 and HDAC leading to full gene activation.Figure 4Co-binding of Histone H3K27 Methyltransferase/Demethylase and Histone Acetyltransferase/Deacetylase to Gene Promoters(A--D) Binding of the H3K27 methyltransferase EZH2 (A), the H3K27 demethylase UTX (B), the histone deacetylase HDAC1 (C), and the histone acetyltransferase p300 (D) to indicated gene promoters was measured by ChIP-qPCR. ChIPs were performed using indicated antibodies (Ab) or IgG as a negative control (Mock). qPCR values are expressed as mean fractions of input ±SD.(E) Model representing co-binding of antagonistic enzymes on gene promoters such that transcription is maintained at low levels (poised gene). Combined inhibition of the repressive enzymes EZH2 and HDAC1 displaces the equilibrium leading to transcriptional activation.

Gene Activation Mediated by HDAC and EZH2 Inhibitors Is a Reversible Process {#sec2.4}
----------------------------------------------------------------------------

Co-binding of antagonistic chromatin-modifying enzymes on bivalent gene promoters ([Figure 4](#fig4){ref-type="fig"}) predicts that gene activation through pharmacologic inhibition of HDACs and EZH2 will be reversible upon drug removal. To test this hypothesis, ECFCs were treated with a combination of GSK-343 and panobinostat. Then, treated ECFCs were harvested, washed, and re-plated in the absence of the epigenetic drug cocktail. Measuring gene expression and histone PTMs at several time points after re-plating, we observed both increased H3K27me3 and decreased H3-Ac at promoters of pro-angiogenic genes upon drug removal ([Figures 5](#fig5){ref-type="fig"}B and 5C). Furthermore, after 24 hr, the pro-angiogenic genes had reverted back to their native transcriptionally repressed status ([Figure 5](#fig5){ref-type="fig"}A). Taken together, these results confirm the transient nature of panobinostat-/GSK-343-mediated epigenetic modifications at pro-angiogenic genes in ECFCs.Figure 5Gene Activation upon Treatment with a Combination of HDAC and EZH2 Inhibitors Is Reversible(A) Transcript levels of indicated genes were measured by qRT-PCR at the indicated times after removal of the GSK-343/panobinostat drug combination. qRT-PCR values are expressed as mean percentages of vehicle-treated cells ±SEM with *B2M* serving as internal control. (n = 3).(B and C) Enrichment of H3K27me3 (B) and H3 acetyl (C) histone marks is measured by ChIP-qPCR at the indicated times after removal of the GSK-343/panobinostat drug combination. qPCR values are expressed as mean fractions of input ±SD.^∗∗∗^p \< 0.001; ^∗∗^p \< 0.01; ^∗^p \< 0.05; ns, non-significant.

Pharmacologic Inhibition of HDAC and EZH2 Increases ECFC-Mediated Vasculogenesis and Improves the Therapeutic Potential of Transplanted ECFCs in a Hindlimb Ischemia Mouse Model {#sec2.5}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The results described above revealed that several major pro-angiogenic transduction pathways are activated in ECFCs through pharmacologic inhibition of EZH2 and HDACs. To determine whether these effects translate into increased vasculogenesis *in vivo*, ECFCs were pretreated with GSK-343 and panobinostat prior to embedding into collagen matrices that were subcutaneously implanted into immunodeficient mice ([@bib42]). After 3 weeks, implants were harvested and analyzed for blood-vessel formation using a human-specific CD31 antibody as previously described ([@bib42]). This experiment revealed the formation of ECFC-derived micro-capillaries ([Figure 6](#fig6){ref-type="fig"}A) where the presence of surrounding murine smooth muscle cells suggests capillary maturation ([Figure S6](#mmc1){ref-type="supplementary-material"}). Furthermore, the number of these human, ECFC-derived capillaries is significantly increased in implants from drug-treated ECFCs ([Figure 6](#fig6){ref-type="fig"}A, right panel), confirming the efficacy of combined GSK-343 and panobinostat treatment in improving ECFC-derived vasculogenesis *in vivo*.Figure 6Pharmacologic Treatment with a Combination of EZH2 and HDAC Inhibitors Accelerates Vasculogenesis and Blood-Flow Recovery by Transplanted ECFCs in a Mouse Model of Hindlimb Ischemia(A) H&E staining (left) and anti-human (h) CD31 staining (right) identify ECFCs that have formed micro-capillaries in collagen gels after 3 weeks of implantation in mice (scale bar, 200 μm). Numbers of fully closed ECFC-derived hCD31+ capillaries are indicated per measured explanted area as mean values ± SEM (n = 6 mice per group).(B) Laser Doppler perfusion imaging was used to measure blood flow pre-operatively (pre-op), immediately after induction of hindlimb ischemia (day 0) and at the indicated time points after injection of ECFCs pretreated with vehicle or with the drug combination. Left: representative laser Doppler images (Isch., Ischemic leg; NI, non-ischemic leg). Right: perfusion ratios (Isch./NI) are indicated as mean values ± SEM (ECFCs: days 0--14, n = 7 mice; days 21--28, n = 3 mice. ECFCs treated: days 0--14, n = 8 mice; days 21--28, n = 4 mice).(C) EZH2 and HDAC inhibitors upregulate multiple transduction pathways in ECFCs.Schematic representation of cell-signaling molecules and processes that are upregulated (red) or downregulated (green) upon treatment of ECFCs with the GSK-343 and panobinostat combination.^∗∗^p \< 0.01; ^∗^p \< 0.05. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

Finally, we sought to determine the extent to which *ex vivo* treatment with epigenetic drugs enhances the vascular repair function of ECFCs. To address this question, we used a murine model of hindlimb ischemia ([@bib30], [@bib38]), where ischemia is induced by ligation of the left femoral artery, followed by intramuscular injection of treated or non-treated ECFCs as cell therapy. This experiment revealed that ECFCs pretreated *ex vivo* with GSK-343 and panobinostat are more rapid at restoring blood flow in the ischemic leg compared with their non-treated counterparts ([Figure 6](#fig6){ref-type="fig"}B). Specifically, by measuring blood flow using Doppler analysis at several time points after cell therapy, we found that the kinetics of blood-flow recovery in the ischemic leg is significantly accelerated when GSK-343-panobinostat-treated ECFCs are used for transplantation ([Figure 6](#fig6){ref-type="fig"}B). This improvement is therapeutically relevant given that the speed of blood-flow recovery is one of the most important factors in saving organ function after acute ischemia ([@bib8], [@bib13]). Furthermore, the improved perfusion persists for at least 4 weeks post transplantation in mice injected with either drug-treated or non-treated ECFCs ([Figure 6](#fig6){ref-type="fig"}B). Thus, pre-activation of ECFCs with a cocktail of epigenetic drugs (i.e., EZH2 and HDAC inhibitors) administered *ex vivo* is a promising strategy to increase the therapeutic potential of these cells and boost their vascular repair function *in vivo* through increased activity of multiple pro-angiogenic signaling pathways ([Figure 6](#fig6){ref-type="fig"}C).

Discussion {#sec3}
==========

ECFCs are human endothelial progenitor cells with unique capabilities to form vascular structures in several animal models of ischemia ([@bib38], [@bib41]). However, these cells have not been fully characterized and additional strategies are needed to improve their therapeutic potential. Here, we show that ECFCs maintain several key pro-angiogenic pathways (i.e., NOTCH, WNT, CXCR4, VEGFR, and SHH) in a repressed/poised state through the establishment of bivalent gene promoters that are characterized by the simultaneous enrichment of active and repressive histone PTMs. This equilibrium is maintained by epigenetic enzymes with competing activities (i.e., EZH2/UTX and P300/HDAC1) that are co-bound to gene promoters, resulting in low expression levels. *In vivo*, ECFCs presumably require external signals from the environment to fully activate pro-angiogenic pathways in response to vascular injury. Interestingly, our results indicate that this activation process can be initiated *ex vivo* prior to transplantation through pharmacologic approaches with specific EZH2 and HDAC inhibitors. Importantly, this *ex vivo* "boosting" procedure that leads to the activation of multiple pro-angiogenic pathways in ECFCs is translated *in vivo* by enhanced vasculogenesis, angiogenesis, and accelerated vascular repair in a hindlimb ischemia model. Furthermore, the reversible nature of epigenetic modifications ensures that the injected cells remain responsive to signals from the environment, optimizing vascular repair to the host\'s specific needs and limiting potential adverse effects such as blood-vessel overgrowth.

In this study, we have focused on histone modifications enriched on promoters of specific genes that belong to pro-angiogenic pathways. Future studies, using genome-wide approaches, are necessary to identify the full extent of bivalent promoters in ECFCs. Furthermore, bivalent marks have also been identified on distal regulatory elements ([@bib35]), suggesting that our epigenetic drug cocktail may also affect the epigenetic state of enhancers. A detailed understanding of enhancer/promoter communications in ECFCs, as determined by chromosome conformation capture (3C) approaches ([@bib15]), will be required as a pre-requisite to appreciate the full extent of epigenetic changes occurring upon drug treatment and their consequences on gene expression and vascular repair.

Experimental Procedures {#sec4}
=======================

Cell Isolation and Culture {#sec4.1}
--------------------------

All procedures were approved by the Ottawa Hospital Research Ethics Board (2007804-01H). Human ECFCs were derived from umbilical cord blood obtained after informed consent from the Canadian Cord Blood for Research Program (2014.007) and cultured as previously described ([@bib38], [@bib50]). Briefly, mononuclear cells were isolated by Ficoll density gradient centrifugation and seeded onto CellBIND sux-well plates (Corning) at a density of 10^7^ mononuclear cells/well in EGM-2 BulletKit medium (Lonza) supplemented with 10% fetal bovine serum. Individual ECFC colonies were re-plated separately and analyzed by flow cytometry (CD31+/CD34+/CD45−) after each passage. All experiments were performed with at least three biologically independent ECFC clones between passage 3 and 6.

Capillary-like Network Formation Assay {#sec4.2}
--------------------------------------

ECFCs, pretreated with epigenetic drugs or vehicle as indicated, were seeded into 96-well plates previously coated with 50 μL of phenol-red-free, growth factor reduced Matrigel (Corning) at a density of 5,000 cells/well in duplicates. After 24 hr, cells were stained with 5 μg/mL calcein (BD Bioscience) for 5 min at 37°C and photographed using an Axiovert S100 microscope (Zeiss) and AxioVision 4.6 software at 2.5× magnification. Total tube length was quantified using AngioQuant software as described ([@bib20]).

Cell Migration Assay by Gap Closure {#sec4.3}
-----------------------------------

ECFC migration was measured by gap closure assay using the Radius 96-well cell migration assay (Cell Biolabs) according to the manufacturer's instructions. Briefly, 2 × 10^4^ ECFCs, pretreated with epigenetic drugs or vehicle, were seeded into a 96-well plate containing a hydrogel plug and allowed to adhere onto the plate. The plug was removed providing a cell-free area, and cell migration into the gap was monitored by taking pictures every 3 hr using an Axio Observer.A1 microscope (Zeiss) and AxioVision 4.6 software at 10× magnification. Once confluent, cells were labeled with crystal violet (Cell Biolabs). The cell-free area was measured using MATLAB software, which provides a simple graphical user interface through which a user can select an image to calculate the area automatically or manually. Automatic segmentation begins with gray-level thresholding of the input image, then SD filtering on the thresholded image, followed by a series of morphological operations to detect the cell-free area and calculate the area size in pixels.

Serum Starvation and Apoptosis Assay by Annexin V Staining {#sec4.4}
----------------------------------------------------------

ECFCs were plated into 6-well plates containing EBM-2 medium without addition of EGM-2 SingleQuots (Lonza) and incubated overnight (16 hr) prior to harvesting and suspension in annexin V binding buffer (BD Pharmingen). Apoptosis was then assessed using the Annexin V PE Apoptosis Detection Kit I (BD Pharmingen) according to the manufacturer\'s instructions.

ECFC Transplant in NOD/SCID Mice {#sec4.5}
--------------------------------

Three-dimensional cellularized collagen matrices were prepared as previously described using the Standardized Oligomer Polymerization Kit (GeniPhys, Indiana, USA) ([@bib41]). Briefly, type I collagen gels (1.5 mg/mL) were prepared on ice, mixed immediately with ECFCs (4 × 10^6^ cells/mL) that had been treated (or not) with the epigenetic drug cocktail as indicated, and left to polymerize for 30 min at 37°C in a CO~2~ incubator prior to the addition of 500 μL of culture medium in the absence of GSK-343 and panobinostat. After 18 hr incubation, cellularized gels were implanted into the flanks of 6- to 12-week-old NOD/SCID mice, as described ([@bib42]). Surgical procedures were conducted under anesthesia and a constant supply of oxygen. Three weeks after implantation, gels were recovered from animals that had been humanely euthanized per approved IACUC protocol.

Histology was performed using H&E stain and immunohistochemistry using an anti-human CD31 antibody. Briefly, gel explants were formalin fixed, processed, and embedded in paraffin, followed by serial sectioning (4 μm) using a Leica microtome. Paraffin-embedded tissue sections were deparaffinized in xylene and rehydrated through a 100%--70% ethanol gradient. Heat-induced epitope retrieval was performed at 110°C, 12 min with EDTA buffer (pH 9.0), and 3% H~2~O~2~ was used to block endogenous peroxidases. Sections were blocked with Background Sniper reagent (BioCare Medical, CA, USA) and incubated with mouse anti-hCD31 Ab (DAKO, clone JC70A) for 1 hr at room temperature (1:2,000 dilution). The MACH4+ DAB detection system was used according to the manufacturer's instructions (BioCare Medical, CA, USA). ECFC-derived hCD31+ blood vessels were imaged using an Aperio ScanScope XT (Leica Microsystems).

Mouse Model of Hindlimb Ischemia {#sec4.6}
--------------------------------

ECFC-induced vascular repair was assessed using a hindlimb ischemia mouse model as described ([@bib27], [@bib38]). All procedures were approved by the University of Ottawa Animal Care Committee and performed in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals. Ischemia was induced in the left hindlimb of 8-week-old athymic nude CD1 female mice by ligation of the proximal end of the femoral artery. ECFCs were injected immediately after skin closure. Specifically, 5 × 10^5^ ECFCs, pretreated with the drug combination or vehicle as indicated, were re-suspended in 50 μL of PBS and delivered by two equivolumetric injections into the adductor muscle, downstream of the unilateral left hindlimb ligation site, using an insulin syringe. Blood perfusion was monitored pre-operatively, immediately after surgery, and at the indicated days post operation by laser Doppler perfusion imaging (moorLDI2; Moor Instruments). Results are expressed as the ratio of ischemic to non-ischemic hindlimb perfusion. For non-treated ECFCs, seven mice were monitored up to 14 days, three of which were maintained for up to 4 weeks to evaluate the persistence of blood perfusion. For drug-treated ECFCs, eight mice were monitored up to 14 days, four of which were maintained for up to 4 weeks to evaluate the persistence of blood perfusion.

RNA Extraction, Gene Expression Profiling by RNA Sequencing, and Bioinformatics Analysis {#sec4.7}
----------------------------------------------------------------------------------------

For RNA-seq, we used two independent ECFC clones (clone A and clone B) at passage 3 originating from two distinct cord blood samples, as well as clone A at passage 4 (i.e., clone A′). Clones A, A′, and B were treated with epigenetic drugs or vehicle independently of each other, and therefore represent three biological replicates. For each clone, total RNA was extracted from 10^6^ ECFCs using the RNeasy Mini Kit (QIAGEN), including a genomic DNA digestion step with DNase I (QIAGEN), and analyzed by high-throughput sequencing as previously described ([@bib5]).

Chromatin Immunoprecipitation {#sec4.8}
-----------------------------

Analysis of histone modifications was performed by native chromatin immunoprecipitation (ChIP) as described ([@bib7]). Cofactor binding was assessed by crosslink ChIP as described ([@bib38]). ChIPed DNA was purified by phenol-chloroform extraction, precipitated with ethanol, and specific DNA sequences were amplified with PerfeC TaSYBRGreen SuperMix (Quanta Biosciences) using a Rotor-Gene Q real-time PCR system (QIAGEN). ChIPed DNA quantity was calculated compared with a genomic DNA standard curve using Rotor-Gene Q Series Software 1.7 (QIAGEN) with R^2^ \> 0.96.

Statistical Analyses {#sec4.9}
--------------------

Data obtained from at least three independent experiments each in duplicate or triplicate were expressed either as mean values or percentages of control values ± SD or SEM. When indicated, statistical significance between data groups was determined by non-parametric Kruskal-Wallis test followed by Dunn's post hoc test, or parametric one- or two-way ANOVA followed by Dunnett or Bonferroni post hoc test using GraphPad Prism 5 software. Use of the non-parametric Kruskal-Wallis test or ANOVA was determined depending on their distribution assessed by the Shapiro-Wilk normality test. Data are considered to be significantly different at p \< 0.05. The p values are depicted with asterisks in the figures as follows: ^∗∗∗^p \< 0.001; ^∗∗^p \< 0.01; ^∗^p \< 0.05; ns, non-significant; ND, non-determined.
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